CytoDyn says Biomm SA to submit authorization request to conduct Phase 3 clinical studies of leronlimab with ANVISA in Brazil
CytoDyn says Biomm SA to submit request to conduct Phase 3 clinical studies of leronlimab with ANVISA in Brazil The company will conduct two Phase 3 trials for a batch of critically ill coronavirus patients, and another severely ill population Once approved by ANVISA, the Phase 3 trials will be conducted by the Albert Einstein Israelite Hospital in Brazil CytoDyn Inc (OTCQB:CYDY), which is developing Vyrologix (leronlimab-PRO 140) for multiple indications, has said that its Brazilian distribution partner Biomm SA (BVMF:BIOM3) plans to submit an authorization request to the Brazi...